MEI Pharma, Inc. (MEIP)

Market Cap	22.45M
Revenue (ttm)	72.65M
Net Income (ttm)	19.84M
Shares Out	6.66M
EPS (ttm)	2.97
PE Ratio	1.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,477
Open	3.220
Previous Close	3.250
Day's Range	3.220 - 3.370
52-Week Range	3.200 - 7.970
Beta	0.64
Analysts	Buy
Price Target	43.50 (+1,190.8%)
Earnings Date	May 9, 2024

About MEIP

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2003
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: MEIP

Financial Performance

In 2023, MEI Pharma's revenue was $48.82 million, an increase of 19.95% compared to the previous year's $40.70 million. Losses were -$31.84 million, -41.53% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is $43.5, which is an increase of 1,190.80% from the latest price.

Price Target

$43.5

(1,190.80% upside)

Analyst Consensus: Buy